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We report the case of a 38-year-old male with autosomal-dominant polycystic kidney 
disease (ADPKD) and concomitant nephrotic syndrome secondary to membranous 
nephropathy (MN). A 3-month course of prednisone 60 mg daily and losartan 100 mg 
daily resulted in resistance. Treatment with chlorambucil 0.2 mg/kg daily, low-dose 
prednisone, plus an angiotensin-converting enzyme inhibitor (ACEI) and an angiotensin 
II receptor blocker (ARB) for 6 weeks resulted in partial remission of his nephrotic 
syndrome for a duration of 10 months. After relapse of the nephrotic syndrome, a 13-
month course of mycophenolate mofetil (MFM) 2 g daily and low-dose prednisone 
produced complete remission for 44 months. After a new relapse, a second 24-month 
course of MFM and low-dose prednisone produced partial to complete remission of 
proteinuria with preservation of renal function. Thirty-six months after MFM withdrawal, 
complete remission of nephrotic-range proteinuria was maintained and renal function 
was preserved. This case supports the idea that renal biopsy is needed for ADPKD 
patients with nephrotic-range proteinuria in order to exclude coexisting glomerular 
disease and for appropriate treatment/prevention of renal function deterioration. To the 
best of our knowledge, this is the first reported case of nephrotic syndrome due to MN in 
a patient with ADPKD treated with MFM, with remission of proteinuria and preservation of 
renal function after more than 10 years. Findings in this patient also suggest that MFM 
might reduce cystic cell proliferation and fibrosis, preventing progressive renal scarring 
with preservation of renal function.  
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INTRODUCTION  
Autosomal-dominant polycystic kidney disease (ADPKD) is an inherited disorder characterized by the 
development and growth of cysts in the kidneys. Mild proteinuria, <1 g/day, is a common finding in 
patients with ADPKD[1]. However, association with nephrotic syndrome is considered to be rare in this 
disorder[2,3,4]. Therefore, massive proteinuria in ADPKD patients should raise the suspicion of a 
complicating glomerular disease. We report a patient with ADPKD who developed nephrotic syndrome 
and renal biopsy showed membranous nephropathy (MN). The patient was treated with mycophenolate 
mofetil (MFM) and 36 months after MFM withdrawal, complete remission of nephrotic-range proteinuria 
was maintained and renal function was well preserved. 
CASE REPORT 
A 38-year-old man with ADPKD presented in April 2000 with a 4-week history of generalized edema. He 
had hyperlipidemia, hypoalbuminemia, and proteinuria of 11.8 g/24 h. Serum creatinine was 1 mg/dl 
(76.26 µmol/l) and creatinine clearance was 109 ml/min/1.73 m
2
. Tests for HBsAg, HCV-ab, HIV, 
VDRL, and ANA were negative. Serum C3 and C4 levels were normal. Abdominal ultrasound (US) and 
computed tomography (CT) showed both kidneys with multiple small cysts, with the right kidney 
measuring 11.7 cm in length with a 5-cm cyst at the superior pole, and the left kidney measuring 13 cm in 
length with a 1.5-cm sinusal cyst. At this point, a US-guided renal biopsy was performed. Light 
microscopy revealed 12 glomeruli showing normal size and cellularity, global diffuse capillary wall 
thickening with subepithelial fuchsinophilic deposits, and widespread epimembranous spikes with 
methenamine silver staining (Fig. 1A). Immunofluorescence (IF) studies showed global diffuse fine 
granular deposition of IgG (3+), C3 (2+), and fibrinogen (1+) along the peripheral capillary loops (Fig. 
1B). Based upon these findings, stage II idiopathic MN was diagnosed, and treatment started with oral 
prednisone (60 mg/day) and losartan (100 mg/day). After 3 months of steroid treatment without response, 
prednisone was tapered. In January 2001, treatment with chlorambucil 0.2 mg/kg/day and prednisone 20 
mg/day for 6 weeks, together with an angiotensin-converting enzyme inhibitor (ACEI) (enalapril) and an 
angiotensin II receptor blocker (ARB) (telmisartan), resulted in partial remission of the nephrotic 
syndrome. Ten months after chlorambucil withdrawal, relapse of the nephrotic syndrome occurred. In 
December 2001, he received treatment with MFM (2 g/day) and prednisone (20 mg/day), which were 
maintained for 13 months. The proteinuria gradually decreased to <0.5 g/24 h and renal function 
remained stable. Forty-four months after MFM withdrawal, proteinuria relapsed. Then, in December 
2005, MFM (2 g/day) and prednisone (20 mg/day subsequently tapered) were reinitiated. 
Hypercholesterolemia was diagnosed and treated with atorvastatin 20 mg daily. The proteinuria gradually 
decreased to about 1 g/24 h and MFM was maintained for 24 months. In May 2008, abdominal magnetic 
resonance imaging (MRI) showed conserved kidney form with multiple small cysts (4–10 mm), the right 
kidney with a 6-cm cyst at the superior pole and the left kidney with several 2- to 3.5-cm sinusal cysts. 
The liver also displayed multiple cysts. In February 2009, proteinuria ranged from 0.7 to 1.4 g/24 h, 
serum creatinine was 1.1 mg/dl (83.89 µmol/l), and creatinine clearance was 93 ml/min/1.73 m
2
. In 
October 2010, 36 months after MFM withdrawal, proteinuria was 0.4 g/24 h, serum creatinine was 1.1 
mg/dl (83.89 µmol/l), and creatinine clearance was 114 ml/min/1.73 m
2
. Serum total cholesterol levels 
remained controlled with treatment, with atorvastatin 20 mg daily. His treatment with both an ACEI and 
an ARB is continuing. The clinical evolution is summarized in Table 1. 
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FIGURE 1. (A) Light microscopy image showing segmental 
subepithelial fuchsinophilic deposits (hematoxylin eosin). (B) IF 
showing diffuse granular deposits of IgG.  
DISCUSSION 
Although mild proteinuria has been reported to occur in ADPKD[1], nephrotic syndrome is exceptional 
and its presence should raise the possibility of complicating glomerular disease[2,3]. Hiura et al.[3] 
reported an ADPKD patient with IgA nephropathy and reviewed 21 cases of ADPKD, including cases in 
the English and Japanese literature, in which the renal lesion was evaluated by histopathologic studies. Of 
the 21 patients, focal segmental glomerulosclerosis and minimal change nephropathy were the dominant 
diagnoses, with five patients each. Next in frequency was MN, with three patients, and IgA nephropathy, 
with two patients. Six other patients had a variety of diagnoses (diabetes, amyloidosis, 
mesangioproliferative and crescentic glomerulonephritis). There is only one report of ADPKD with 
nephrotic syndrome secondary to lupus nephritis[4]. Sar et al.[5] reported a new case of secondary 
amyloidosis and ADPKD. D'Cruz et al.[6] reported a case of ADPKD with nephrotic-range proteinuria and 
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TABLE 1 
Evolution of an ADPKD Patient with Nephrotic Syndrome and MN 
Date Proteinuria 
g/24 h 
Cr  
mg/dl (μmol/l) 
Cr Cl 
ml/min/1.73 m
2
 
Treatment and Outcome  
June 2000 11.8 1.0 (76.26) 109 Prednisone (3 months) 
Resistance 
January 2001 11.5 1.2 (91.51) 105 Chlorambucil (6 weeks) + Prednisone   
Partial remission 
December 2001 26.9 1.2 (91.51) 104 Mycophenolate (13 months)  + Prednisone  
Complete remission 
December 2005 6.2 1.0 (76.26) 106 Mycophenolate + Prednisone  
Partial remission 
October 2006 2.2 0.9 (68.63) 136 Mycophenolate  
Partial remission 
October 2007 1.0 1.1 (83.89) 109 Mycophenolate  
Partial-complete remission 
February 2009 1.4 1.1 (83.89) 93 Enalapril + Telmisartan 
Partial-complete remission 
October 2009 1.7 1.2 (91.51) 95 Enalapril + Telmisartan 
Partial-complete remission 
January 2010 0.3 1.3 (99.14) 104 Enalapril + Telmisartan 
Complete remission 
April 2010 0.7 1.3 (99.14) 112 Enalapril + Telmisartan 
Complete remission 
October 2010 0.4 1.1 (83.89) 114 Enalapril + Telmisartan 
Complete remission 
histologically proven poststreptococcal diffuse proliferative glomerulonephritis. Recently, a case of 
steroid-sensitive nephrotic syndrome[7] and a new case of MN have been reported[8] in children. Since 
there is no apparent pathogenic link between ADPKD and the different causes of nephrotic syndrome that 
have been reported in ADPKD patients, it suggests that they are likely coincidental diseases. The 
evaluation of the data of these patients suggests that the presence of concomitant glomerular disease may 
accelerate the course of ADPKD toward end-stage renal disease (ESRD) and may require specific 
treatment to control the proteinuria. Importantly, proteinuria and hypertension are independent risk factors 
for the development of ESRD in ADPKD[1]. At present, it is impossible to assess the potential benefit of 
measures leading to a decrease in the proteinuria in the progression of ADPKD toward ESRD. In 
addition, currently there is no effective treatment available to retard cyst growth and to prevent 
progression to ESRD in patients with ADPKD. Thus, although spontaneous remission of the 
glomerulopathy cannot be completely excluded in our ADPKD patient, the nephrotic syndrome was 
apparently responsive to treatment with MFM, so the patient could be considered a lucky responder to 
MFM. Furthermore, he maintained complete remission of nephrotic-range proteinuria and stable renal 
function after more than 10 years. One possible explanation for this finding is that MFM might reduce 
cystic cell proliferation, angiogenesis, and fibrosis, preventing progressive renal scarring[9,10] with 
preservation of renal function. Although the explanation about possible beneficial influences of MFM on 
the clinical evolution of ADPKD in this patient can appear speculative, MFM has proven highly effective 
in reducing renal cystogenesis and loss of renal function in an animal model of polycystic kidney 
disease[10]. However, the effect of MFM in kidney volume and renal function of ADPKD patients has 
not been established.  
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The evaluation of the data of these patients also revealed that only anecdotal case reports of ADPKD 
received a US- or CT-guided percutaneous renal biopsy[4,8], while the remaining patients received an 
open surgical biopsy[2,3,6]. The renal biopsy is an invaluable tool in the diagnosis, prognosis, and 
management of patients with kidney disease. The cost-benefit ratio reaches high levels because it is able 
to define abnormal kidney situations to a profound extent. Uncertain nephropathies, proteinuria and 
glomerular-origin hematuria, other urine sediment abnormalities, interstitial disease, and transplanted 
patients are among the situations recognized as definitely benefiting from kidney biopsy. Occasionally 
apparent simple nephropathies are present as complex situations associating renal syndromes 
pathogenically diverse. This is the case of ADPKD associated with the nephrotic syndrome. It opened the 
necessity of performing a kidney biopsy in a cystic nephropathy. In this case, just the complementary 
histological study was able to define the glomerular situation in appearance pathogenically separated from 
the principal process, the cystic degenerative change of renal parenchyma. The percutaneous renal biopsy 
has been established as a safe and effective method of obtaining renal parenchyma. With newer 
technology, the use of real-time US guidance and automated biopsy needles has improved the rate of 
successful diagnosis in over 95% of cases[11]. US can localize the desired lower pole site, determine 
renal size, and detect the presence of large cysts that might necessitate using the contralateral kidney. CT-
guided renal biopsy is an alternative when the kidneys cannot be well visualized, as with marked obesity 
or small echogenic kidneys. Complications, although rare, may occur and the majority of these are related 
to bleeding. However, there are absolute and relative contraindications, such as solitary kidney, 
uncontrolled arterial hypertension, hemostasis disorders, renal artery aneurysm, Jehovah witness, 
percutaneous needle renal biopsy failure, morbid obesity, and noncollaborative patients. In patients with 
contraindications to the percutaneous approach, alternative methods of obtaining tissue have been 
attempted. In these situations, open renal biopsy is the option through flank or posterior incision. Because 
multiple bilateral cysts is listed as a relative contraindication to percutaneous renal biopsy, due to the 
presumed risk of complications and difficulties in obtaining suitable tissue for diagnosis, a majority of 
polycystic kidney disease patients received an open surgical biopsy[2,3,4]. This literature consisted 
mostly of case reports and there are no published trials. Only in some few cases of polycystic kidney 
disease, including our patient, US- or CT-guided renal biopsy was performed without complications[6]. 
However, the experience with this practice is too limited to recommend it safely for widespread practice. 
Although the open, or surgical, renal biopsy has been performed for more than 40 years as the standard 
procedure in patients with contraindications to the percutaneous approach, alternative methods that may 
be less invasive have been pursued. These include laparoscopic, transurethral, or transvenous renal 
biopsy[11,12,13,14,15]. The transvenous biopsy technique uses the native vessels as an alternate route to 
an organ. The tissue specimen is obtained from inside out by passing the needle through the vein wall into 
the surrounding parenchyma[12,13,14,15,16]. The theoretical advantages are that bleeding occurs back 
into the vein; the needle is directed away from, rather than toward, the larger organ vessels; and there is 
less likelihood of capsular perforation. Disadvantages include smaller sample size (and thus decreased 
diagnostic yield) and limited availability of technical expertise. This procedure may be an option in 
selected circumstances when the appropriate expertise is available. There were no published trials with 
this procedure in patients with polycystic kidney disease. Laparoscopic renal biopsy can be performed via 
a laparoscopic retroperitoneal (retroperitoneoscopy)[17,18,19] or transperitoneal approach[20]. These 
methods of biopsy are advantageous in that the kidney is positively identified, and that cortical biopsy and 
hemostasis are achieved under direct vision. In addition, because laparoscopic retroperitoneal renal biopsy 
is minimally invasive, recovery and convalescence are short for most patients[17,19], and the technique 
can be performed on an outpatient basis. The retroperitoneal endoscopic approach has gained popularity 
both worldwide and in our country, including indications in pediatric cases[21,22]. In fact, the 
retroperitoneoscopy or transperitoneal approach renal biopsy is now the preferred procedure for pediatric 
patients[23]. A new approach combining laparoscopy and percutaneous needle biopsy has been 
proposed[24]. This approach combines the advantages of percutaneous biopsy, with minimal trauma to 
the kidney and the low morbidity associated with laparoscopy. Although laparoscopic surgery is highly 
efficacious and is associated with high satisfaction rates with minimal morbidity in the management of 
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renal cystic disease[25], a review of the literature revealed only anecdotal case reports of patients with 
multiple bilateral renal cysts receiving a laparoscopic renal biopsy. Therefore, we believe that patients 
with polycystic kidney disease who require a kidney biopsy for complex situations will benefit from 
laparoscopy-guided kidney biopsy with an appropriate risk-benefit ratio. Under this technique, the direct 
access to the organ permits both selecting the tissue area to be biopsied and attending to any structure 
injured during the procedure. 
In summary, this case underlines the need for renal biopsy in patients with ADPKD and nephrotic-
range proteinuria, with or without an accompanying decline in renal function, in order to make an 
accurate diagnosis and for appropriate treatment/prevention of renal function deterioration. With advances 
in endoscopic instrumentation, the development of laparoscopic-guided retroperitoneal renal biopsy now 
provides a minimally invasive alternative to open renal biopsy in the presence of large cysts. To our 
knowledge, this is the first reported case of nephrotic syndrome due to MN in a patient with ADPKD 
treated with MFM, with complete remission of nephrotic-range proteinuria and preservation of renal 
function after more than 10 years.  
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